Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website
Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website
This is an increase over the number of companies cited in the previous year.
The citations in the county include:
- You offered food-producing animal(s) for interstate commerce that was found to bear or contain a drug residue in an edible tissue above an established safe level, safe concentration, or tolerance.
- You did not maintain complete treatment records.
- The responsibilities and procedures applicable to the quality control unit are not in writing.
The companies cited were involved in either Veterinary or Drugs sectors.
Both companies cited should take voluntary actions to correct their managing operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
Aura Cacia | Drugs | 12/01/2023 | Procedures not in writing, fully followed |
Aura Cacia | Drugs | 12/01/2023 | Component identity verification |
Aura Cacia | Drugs | 12/01/2023 | Absence of Written Procedures |
Aura Cacia | Drugs | 12/01/2023 | Label storage access limited to authorized personnel |
Aura Cacia | Drugs | 12/01/2023 | Expiration date lacking |
Genosource | Veterinary | 12/18/2023 | Introduction/delivery into IS - illegal drug residue |
Genosource | Veterinary | 12/18/2023 | Record keeping |